{
    "title": "108_s2053",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medicare Enhancements for Needed \nDrugs Act of 2004''.\n\nSEC. 2. GAO STUDIES AND REPORTS ON PRICES OF PRESCRIPTION DRUGS.\n\n    (a) Review and Reports on Retail Prices of Prescription Drugs.--\n            (1) Initial review.--The Comptroller General of the United \n        States shall conduct a review of the retail cost of \n        prescription drugs in the United States during 2000 through \n        2003, with an emphasis on the prescription drugs most utilized \n        for individuals age 65 or older.\n            (2) Subsequent review.--After conducting the review under \n        paragraph (1), the Comptroller General shall continuously \n        review the retail cost of such drugs through April 1, 2006, to \n        determine the changes in such costs.\n            (3) Reports.--\n                    (A) Initial review.--Not later than September 1, \n                2004, the Comptroller General shall submit to Congress \n                a report on the initial review conducted under \n                paragraph (1).\n                    (B) Subsequent review.--Not later than July 1, \n                2005, January 1, 2006, and July 1, 2006, the \n                Comptroller General shall submit to Congress a report \n                on the subsequent review conducted under paragraph (2).\n    (b) Annual GAO Study and Report on Retail and Acquisition Prices of \nCertain Prescription Drugs.--\n            (1) Ongoing study.--The Comptroller General of the United \n        States shall conduct an ongoing study that compares the average \n        retail cost in the United States for each of the 20 most \n        utilized prescription drugs for individuals age 65 or older \n        with--\n                    (A) the average price at which private health plans \n                acquire each such drug;\n                    (B) the average price at which the Department of \n                Defense under the Defense Health Program acquires each \n                such drug;\n                    (C) the average price at which the Department of \n                Veterans Affairs under the laws administered by the \n                Secretary of Veterans Affairs acquires each such drug; \n                and\n                    (D) the average negotiated price for each such drug \n                that eligible beneficiaries enrolled in a prescription \n                drug plan under part D of title XVIII of the Social \n                Security Act, as added by section 101 of the Medicare \n                Prescription Drug, Improvement, and Modernization Act \n                of 2003 (Public Law 108-173), that provides only basic \n                prescription drug coverage have access to under such \n                plans.\n            (2) Annual report.--Not later than December 1, 2007, and \n        annually thereafter, the Comptroller General shall submit to \n        Congress a report on the study conducted under paragraph (1), \n        together with such recommendations as the Comptroller General \n        determines appropriate.\n\nSEC. 3. INCLUSION OF AVERAGE AGGREGATE BENEFICIARY COSTS AND SAVINGS IN \n              COMPARATIVE INFORMATION FOR BASIC MEDICARE PRESCRIPTION \n              DRUG PLANS.\n\n    Section 1860D-1(c)(3) of the Social Security Act, as added by \nsection 101 of the Medicare Prescription Drug, Improvement, and \nModernization Act of 2003 (Public Law 108-173), is amended--\n            (1) in subparagraph (A)--\n                    (A) in the matter preceding clause (i), by striking \n                ``subparagraph (B)'' and inserting ``subparagraphs (B) \n                and (C)''; and\n                    (B) by adding at the end the following new clause:\n                            ``(vi) Average aggregate beneficiary costs \n                        and savings.--With respect to plan years \n                        beginning on or after January 1, 2007, the \n                        average aggregate costs, including deductibles \n                        and other cost-sharing, that a beneficiary will \n                        incur for covered part D drugs in the year \n                        under the plan compared to the average \n                        aggregate costs that an eligible beneficiary \n                        with no prescription drug coverage will incur \n                        for covered part D drugs in the year.''; and\n            (2) by adding at the end the following new subparagraph:\n                    ``(C) Average aggregate beneficiary costs and \n                savings information only for basic prescription drug \n                plans.--The Secretary shall not provide comparative \n                information under subparagraph (A)(vi) with respect \n                to--\n                            ``(i) a prescription drug plan that \n                        provides supplemental prescription drug \n                        coverage; or\n                            ``(ii) a Medicare Advantage plan.''.\n\nSEC. 4. NEGOTIATING FAIR PRICES FOR MEDICARE PRESCRIPTION DRUGS.\n\n    (a) In General.--Section 1860D-11 of the Social Security Act, as \nadded by section 101 of the Medicare Prescription Drug, Improvement, \nand Modernization Act of 2003 (Public Law 108-173), is amended by \nstriking subsection (i) (relating to noninterference) and by inserting \nthe following:\n    ``(i) Authority To Negotiate Prices With Manufacturers.--In order \nto ensure that beneficiaries enrolled under prescription drug plans and \nMA-PD plans pay the lowest possible price, the Secretary shall have \nauthority similar to that of other Federal entities that purchase \nprescription drugs in bulk to negotiate contracts with manufacturers of \ncovered part D drugs, consistent with the requirements and in \nfurtherance of the goals of providing quality care and containing costs \nunder this part.''.\n    (b) Effective Date.--The amendment made by this section shall take \neffect as if included in the enactment of section 101 of the Medicare \nPrescription Drug, Improvement, and Modernization Act of 2003 (Public \nLaw 108-173).\n\nSEC. 5. DISALLOWANCE OF DEDUCTION FOR ADVERTISING EXPENDITURES OF \n              TAXPAYERS WHO DISCRIMINATE AGAINST FOREIGN SELLERS OF \n              PRESCRIPTION DRUGS TO DOMESTIC CONSUMERS.\n\n    (a) General Rule.--Part IX of subchapter B of chapter 1 of the \nInternal Revenue Code of 1986 (relating to items not deductible) is \namended by adding at the end the following new section:\n\n``SEC. 280I. ADVERTISING EXPENDITURES OF TAXPAYERS WHO DISCRIMINATE \n              AGAINST FOREIGN SELLERS OF PRESCRIPTION DRUGS TO DOMESTIC \n              CONSUMERS.\n\n    ``(a) In General.--No deduction otherwise allowable under this \nchapter shall be allowed for any amount paid or incurred for \nadvertising for the taxable year by any taxpayer who at any time during \nsuch taxable year discriminates against a qualified pharmacy or \nqualified wholesaler in the sale of prescription drugs.\n    ``(b) Advertising.--For purposes of this section, the term \n`advertising' includes direct to consumer advertising and any activity \ndesigned to promote the use of a prescription drug directed to \nproviders or others who may make decisions about the use of \nprescription drugs (other than the provision of free samples).\n    ``(c) Qualified Pharmacy; Qualified Wholesaler.--For purposes of \nthis section--\n            ``(1) Qualified pharmacy.--The term `qualified pharmacy' \n        means any pharmacy located outside the United States which \n        sells prescription drugs to consumers living in the United \n        States.\n            ``(2) Qualified wholesaler.--The term `qualified \n        wholesaler' means any wholesaler located outside the United \n        States which sells prescription drugs to entities selling \n        prescription drugs to consumers living in the United States.\n    ``(d) Discrimination.--For purposes of subsection (a), a taxpayer \nshall be treated as discriminating against a qualified pharmacy or \nqualified wholesaler in the sale of prescription drugs if such taxpayer \npublicly, privately or otherwise refuses to do business with a person \nor entity on the basis that the person or entity will pass along \ndiscounts offered to the person or entity to consumers living in the \nUnited States.''.\n    (b) Clerical Amendment.--The table of sections for part IX of \nsubchapter B of chapter 1 of such Code is amended by adding at the end \nthereof the following new item:\n\n                              ``Sec. 280I. Advertising expenditures of \n                                        taxpayers who discriminate \n                                        against foreign sellers of \n                                        prescription drugs to domestic \n                                        consumers.''.\n    (c) Effective Date.--The amendments made by this section shall \napply to taxable years beginning after the date of the enactment of \nthis Act.\n\nSEC. 6. COST CONTAINMENT INCENTIVES.\n\n    (a) In General.--Section 1860D-42 of the Social Security Act, as \nadded by section 101 of the Medicare Prescription Drug, Improvement, \nand Modernization Act of 2003 (Public Law 108-173), is amended by \nadding at the end the following new subsection:\n    ``(c) Incentives to PDP Sponsors To Negotiate Lower Prices.--\n            ``(1) Authority.--The Secretary is authorized to provide \n        incentive payments to PDP sponsors offering prescription drug \n        plans that provide enrollees with access to negotiated prices \n        used for payment of covered part D drugs under the plans that \n        on average are not more than 10 percent greater than the lesser \n        of--\n                    ``(A) the average price at which the Department of \n                Defense under the Defense Health Program acquires such \n                drugs; or\n                    ``(B) the average price at which the Department of \n                Veterans Affairs under the laws administered by the \n                Secretary of Veterans Affairs acquires such drugs.\n            ``(2) Information from va and dod.--Upon request of the \n        Secretary of Health and Human Services, the Secretary of \n        Defense and the Secretary of Veterans Affairs shall make \n        available to the Secretary of Health and Human Services such \n        information regarding acquisition prices of prescription drugs \n        as the Secretary of Health and Human Services determines is \n        necessary to conduct the incentive payment program under this \n        subsection.\n            ``(3) Application.--No incentive payments may be made under \n        this subsection except pursuant to an application that is \n        submitted and approved in a time, manner, and form specified by \n        the Secretary.\n            ``(4) Funding.--There shall be available to the Secretary \n        from the MA Regional Plan Stabilization Fund under section \n        1858(e) during the period beginning on January 1, 2007, and \n        ending on December 31, 2013, a total of $500,000,000 for making \n        incentive payments under this subsection.\n            ``(5) Annual reports.--For each year in which an incentive \n        payment is awarded under this subsection, the Secretary shall \n        submit a report to Congress containing a description of the \n        operation of the incentive payment program.''.\n    (b) Stabilization Fund Amendments.--Section 1858(e)(1) of the \nSocial Security Act, as added by section 221(c) of the Medicare \nPrescription Drug, Improvement, and Modernization Act of 2003 (Public \nLaw 108-173), is amended--\n            (1) in the matter preceding subparagraph (A), by striking \n        ``2'' and inserting ``3''; and\n            (2) by adding at the end the following new subparagraph:\n                    ``(C) PDP incentive payments.--To provide incentive \n                payments to PDP sponsors pursuant to section 1860D-\n                42(c).''.\n    (c) Effective Date.--The amendments made by this section shall take \neffect as if included in the enactment of the Medicare Prescription \nDrug, Improvement, and Modernization Act of 2003 (Public Law 108-173).\n\nSEC. 7. NAIC REVIEW AND REPORT ON CHANGES IN MEDIGAP POLICIES THAT \n              PROVIDE COVERAGE OF PRESCRIPTION DRUGS CONTAINED IN THE \n              MEDICARE PRESCRIPTION DRUG, IMPROVEMENT, AND \n              MODERNIZATION ACT OF 2003.\n\n    (a) In General.--The Secretary shall request the National \nAssociation of Insurance Commissioners to conduct a review of the \nchanges to the rules relating to medicare supplemental policies that \nprovide prescription drug coverage contained in subsection (v) of \nsection 1882 of the Social Security Act (42 U.S.C. 1395ss), as added by \nsection 104(a) of the Medicare Prescription Drug, Improvement, and \nModernization Act of 2003 (Public Law 108-173).\n    (b) Impact on Medicare Beneficiaries.--The review conducted \npursuant to subsection (a) should focus on the impact the changes \ndescribed in such subsec"
}